Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Cash & Current Investments (2016 - 2025)

ProQR Therapeutics' Cash & Current Investments history spans 6 years, with the latest figure at $107.6 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 32.62% to $107.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $107.6 million, a 32.62% decrease, with the full-year FY2025 number at $107.6 million, down 32.62% from a year prior.
  • Cash & Current Investments hit $107.6 million in Q4 2025 for ProQR Therapeutics, down from $159.7 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for PRQR hit a ceiling of $219.1 million in Q4 2021 and a floor of $91.5 million in Q1 2021.
  • Historically, Cash & Current Investments has averaged $138.8 million across 5 years, with a median of $136.0 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 139.65% in 2021 and later plummeted 55.28% in 2022.
  • Tracing PRQR's Cash & Current Investments over 5 years: stood at $219.1 million in 2021, then plummeted by 55.28% to $98.0 million in 2022, then skyrocketed by 30.59% to $128.0 million in 2023, then rose by 24.77% to $159.7 million in 2024, then crashed by 32.62% to $107.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for PRQR at $107.6 million in Q4 2025, $159.7 million in Q4 2024, and $128.0 million in Q4 2023.